We recently published a list of 11 the most efficient health actions to buy now. In this article, we are going to take a look at Where CVS Health Corporation (NYSE:CVS) opposes other best efficient health actions to buy now.
On April 15, CNBC reported that the executive order focused on President Trump’s health care had won a victory for the sector. Trump ordered his health service to collaborate with the congress to reorganize a law allowing Medicare to negotiate the prices of prescription drugs. The announcement aims to bring a change for which the pharmaceutical company has pressure. Since the negotiation process is included in the legislation, Trump’s decree cannot implement the change itself. However, he ordered the Secretary of Health and Social Services Robert F. Kennedy Jr. to join the hands of the Congress and change it.
CNBC indicated that drug manufacturers have worked to delay the admissibility calendar for small molecule drugs to be available for four -year price negotiations. This usually includes pills and most drugs. This goes hand in hand with the expectation of 13 years until more complex biotechnological drugs are eligible for Medicare price negotiations.
Trump’s executive decree also focuses on reducing health care costs. This comes one day after the administration has established a national security report on the pharmaceutical industry. CNBC qualified the report “a precursor of sectoral prices”.
Medicare’s negotiation powers have been controversial, as drug manufacturers have estimated that they are deleting innovation and have rallied against the negotiation for negotiations to most drugs. The law now allows the government to negotiate the prices of drugs without competition, which includes complex biotechnological or biological drugs after 13 years on the market, but 9 years for their administration as capsules and pills.
Although they did not provide details, the White House officials told journalists that other changes to the negotiation process would lead to more savings than those affected in the first round under the Biden administration. While the Biden administration has negotiated price reductions as high as 79% for the first ten most expensive drugs in the Medicare program, the Trump administration would negotiate the prices of the following 15 drugs. This includes the Ibrance and Xtandi of Pfizer cancer drugs, as well as the successful diabetes of Novo Nordisk and the weight loss treatments Ozempic and Wegovy.
We used Finviz to filter the health care actions and selected the best performers according to their performance from the year to the start of the year (YTD), on May 9, 2025. We also included the number of hedge holders for each stock at 424. The list is sorted in increasing order of the year.
Why do we care about what the hedge funds do? The reason is simple: our research has shown that we can surpass the market by imitating the main choices of stock of the best hedge funds. The strategy of our quarterly newsletter selects 14 shares with small capitalization and high capitalization each quarter and has rendered 275% since May 2014, beating its reference with 150 percentage points (See more details here).
Jim Cramer on CVS Health (CVS): “The amazing reversal of David Joyner continues”
A row of shelves in a retail pharmacy, demonstrating the variety of over -the -counter medicines and products.
YTD performance: 49.19%
Number of hedge holders: 74
CVS Health Corporation (NYSE: CVS) is a health solutions company operating in four segments: social benefits, health services, pharmacy and well-being of consumers, and the company / other. In addition to being a leading pharmacy chain, the company is one of the largest health insurers in the United States thanks to the operations of its subsidiary of Aetna, which classified it fifth on our list of best-efficient health care actions to invest now.
On May 1, Michael Cherny by Leerink Partners reiterated a purchase note for the company with a price target of $ 83.00. The analyst favored CVS Health Corporation (NYSE: CVS) for its positive trajectory, stressing that its T1 2025 tax results show a promising reversal.
The cost of benefits of benefits show signs of stabilization, aligning the expectations of management. Although Aetna’s finances are confronted with certain complexities due to the adjustments of the previous period, the analyst considers trends as strategic stages to support CVS Health Corporation (NYSE: CVS) return to a coherent power of profit. It also has the potential for upward guidance adjustments as trends continue on their stabilization trajectory.
The PBM services management segment (PBM) of CVS Health Corporation (CVS) is also planned to outdo, supported by the introduction of privileged form options and increased growth in areas such as specialized drugs, supporting the purchase note.
In addition, on May 6, Sarah James de Cantor Fitzgerald maintained a purchase note on CVS Health Corporation (NYSE: CVS) and set a price target of $ 71.00.
Overall, CVS rank 5th On our list of healthy health actions to buy now. While we recognize the potential of CVS as an investment, our conviction lies in the conviction that certain AI actions are more promising to provide higher yields and do it within a shorter period. There is a stock of AI that has increased since the beginning of 2025, while the popular AI shares have lost around 25%. If you are looking for a stock of AI more promising than CVS but which is negotiated within 5 times its income, consult our report on this subject Stock ai the cheapest.
